Akero Therapeutics (AKRO) 10-Q2022 Q1 Quarterly report

Filed: 6 May 22, 7:31am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adult, advisory, aforementioned, allocated, allocation, ASP, attack, bidding, biopharmaceutical, booster, British, Cadillac, CDPA, climate, Colorado, composed, confirmed, conflict, COSO, CPA, CPRA, currency, customer, cybersecurity, delisting, denominated, deploying, deprioritize, deprioritizing, developmental, dissemination, dollar, DP, EC, EEA, essential, Euro, excise, flexibility, focused, free, frozen, gastrointestinal, gave, governor, greatly, group, hedging, hypothetical, improperly, inflationary, instated, intermediate, mark, marked, mask, mechanism, military, misread, missed, misstated, moratorium, NaN, nonbinding, objective, Omicron, opportunity, platform, Pound, pre, preserve, purpose, regime, regression, reopening, Russia, stolen, stored, storing, stringent, supervision, top, traditional, transformational, transient, transmit, Treadway, trend, UK, Ukraine, unfair, unregistered, unrestricted, variant, variation, version, Vetter, Virginia, warrant, witnessed

Removed: accrual, afflicted, aggregated, ALT, anniversary, announcing, assist, bank, began, beneficial, Brexit, budgeted, cancel, cancellation, certify, charge, collateralize, Columbia, coordinated, culminating, deductibility, dose, eliminating, escalating, exemption, extend, formally, half, histology, inform, irrevocable, judged, Kingdom, left, long, mission, NDC, nonconvertible, officially, OIG, opt, originally, pioneering, placebo, point, proposal, Realized, reclassified, reflecting, registrational, reimportation, remotely, repurchase, resuming, revised, safest, scaled, Simplifying, stimulate, undetected, utilization

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AKRO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew Cheng, certify pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Akero Therapeutics, Inc. for the quarterly period ended March 31, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and result of operations of Akero Therapeutics, Inc.



Dated: May 6, 2022	/s/ ANDREW CHENG
	Andrew Cheng, M.D., Ph.D.
	President and Chief Executive Officer
	(Principal Executive Officer)

I, William White, certify pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Akero Therapeutics, Inc. for the quarterly period ended March 31, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and result of operations of Akero Therapeutics, Inc.



Dated: May 6, 2022	/s/ WILLIAM WHITE
	William White
	Executive Vice President, Chief Financial Officer and Head of Corporate Development
	(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.